PAVM News and Press, PAVmed Inc.

Lucid Diagnostics Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population PR Newswire Prospective screening study demonstrates excellent EsoGuard s...

PAVmed Subsidiary, Veris Health, Announces Launch of Pilot Program with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute PR Newswire First patients enrolled on the Veris Cancer Care Platform NEW YORK , ...

4,000th Firefighter Undergoes Lucid Diagnostics' EsoGuard® Esophageal Precancer Testing PR Newswire Firefighter #CheckYourFoodTube Precancer Testing Event organized by Mass General Brigham physicians and Boston Firefighters Local 718 IAFF NEW YORK , June...

2024-05-14 11:59:05 ET PAVmed Inc. (PAVM) Q1 2024 Results Conference Call May 14, 2024 08:30 AM ET Company Participants Matt Riley - Director of IR Lishan Aklog - Chairman and CEO Dennis McGrath - CFO Conference Call Participants Anthony Vendetti - Ma...

2024-05-14 02:51:37 ET More on PAVmed Seeking Alpha’s Quant Rating on PAVmed Historical earnings data for PAVmed Financial information for PAVmed Read the full article on Seeking Alpha For further details see: PAVmed Non-GAAP EPS of -$0.99 ...

PAVmed Provides Business Update and First Quarter 2024 Financial Results PR Newswire Lucid strengthens balance sheet and secures a July 17, 2024 MolDX pre-submission meeting date Veris Health completes MOU with The Ohio State's James Cancer Hospital Con...

2024-05-13 12:13:11 ET More on PAVmed PAVmed Inc. (PAVM) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on PAVmed Historical earnings data for PAVmed Financial information for PAVmed Read the full article on Seeking Alpha ...

Lucid Diagnostics Provides Business Update and First Quarter 2024 Financial Results PR Newswire Quarterly EsoGuard ® test volume increased 10 percent Strengthened balance sheet following completion of $29.8 million Series B Preferred Stock Offering ...

Legacy Sponge-on-a-String Esophageal Cell Collection Device Subject of Class II FDA Recall PR Newswire EsophaCap device recalled due to recent publication of serious device failures Lucid Diagnostics' EsoCheck ® unaffected by recall and remains the gold standa...

Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors PR Newswire Final closing yields total gross proceeds of $29.8 million from offering Mr. Matheis serves as President ...